transmitted/founder (T/F) variants are of particular interest, as a maternal or infant HIV vaccine 23 should raise envelope (Env)-specific IgG responses capable of blocking this group of viruses. 24 However, the maternal or infant factors that contribute to selection of infant T/F viruses are not 25 well understood. In this study, we isolated HIV-1 env genes by single genome amplification from 26 16 mother-infant transmitting pairs from the U.S. pre-antiretroviral era Women Infant 27
Transmission Study (WITS). Infant T/F and representative maternal non-transmitted Env 28 variants from plasma were identified and used to generate pseudoviruses for paired maternal 29 plasma neutralization sensitivity analysis. Eighteen out of 21 (85%) infant T/F Env 30 pseudoviruses were neutralization resistant to paired maternal plasma. Yet, all infant T/F viruses 31
were neutralization sensitive to a panel of HIV-1 broadly neutralizing antibodies and variably 32 sensitive to heterologous plasma neutralizing antibodies. Moreover, infant T/F pseudoviruses 33 were overall more neutralization resistant compared to maternal non-transmitted plasma variants 34 (p=0.012). Altogether, our findings suggest that autologous neutralization of circulating viruses 35 by maternal plasma antibodies select for neutralization-resistant viruses that initiate peripartum 36 transmission, raising the spector that enhancement of this response at the end of pregnancy could 37 further reduce infant HIV infection risk. 38 Introduction infected, transmitting mothers for assessment of the impact of maternal plasma neutralization 81 activity against her own viruses has not to our knowledge, been investigated. Thus, despite 82 considerable effort, it remains unclear whether maternal antibody responses impact the risk of 83 vertical transmission of HIV. 84
We recently completed a maternal humoral immune correlates of protection analysis to 85 identify maternal humoral immune responses associated with protection against peripartum HIV 86 infection using samples from the US-based Women and Infants Transmission (WITS) study [20] . 87
The WITS cohort was enrolled prior to the availability of ART prophylaxis as the clinical 88 standard of care in HIV-infected pregnant mothers and their infants, thereby eliminating the 89 strong impact of ART on vertical HIV transmission risk and outcome [21, 22] . Additionally, we 90 controlled for established maternal and infant risk factors associated with vertical transmission, 91 including maternal peripheral CD4+ T cell count, maternal plasma HIV-1 viral load, infant 92 gestational age, and delivery mode by propensity score matching of transmitting and non-93 transmitting women. The results of this immune correlate analysis indicated an association 94 between high levels of maternal antibodies against the HIV-1 Env glycoprotein third variable 95 loop (V3) and reduced MTCT risk [20] . In addition, and more surprisingly, the ability of 96 maternal plasma to neutralize tier 1 viruses (easy-to-neutralize), but not tier 2 (difficult to 97 neutralize) viruses, also predicted decreased risk of vertical transmission of HIV-1. Yet, 98 vertically transmitted HIV variants have been characterized as more difficult to neutralize tier 2-99 like variants [17, [23] [24] [25] [26] . Thus, it was surprising that tier 1 virus neutralizing antibodies were 100 associated with decreased transmission risk. More interestingly, maternal V3-specific 101 monoclonal IgG antibodies isolated from a non-transmitting mother neutralized a large 102 proportion of maternal autologous viruses isolated from her plasma [20] , leading to the conclusion that maternal V3-specific non-broadly neutralizing antibodies, which were previously 104 thought to be ineffective at preventing HIV-1 transmission, might indeed play a role in 105 preventing MTCT. In fact, Moody et.al [27] showed that V3 and CD4 binding site (CD4bs) 106 specific monoclonal antibodies isolated from non-pregnant chronically HIV-infected individuals 107 could also neutralize a large proportion of autologous circulating viruses isolated from plasma. 108
These V3 and CD4bs-specific autologous virus-neutralizing mAbs exhibited tier 1 neutralization 109 activity but limited heterologous tier 2 virus neutralization, suggesting that measurement of tier 2 110 heterologous virus neutralization potency of mAbs or plasma does not predict autologous virus 111 neutralization capacity. 112
In contrast to the extensive genetic diversity of HIV-1 variants in a chronically infected host, 113 acute HIV infection in both heterosexual and vertical routes are characterized by a homogeneous 114 viral population [17, 18, [28] [29] [30] [31] . This viral genetic bottleneck suggests the selective transmission 115 of a single or homogeneous group of viruses [4] . In the setting of MTCT, maternal or infant 116 immunologic and virologic factors that that drive the selective transmission of one or a few HIV 117 variants are not established [32] . As maternal viruses co-circulate with maternal HIV Env-118 specific antibodies, it is possible that maternal antibodies play a role in selecting maternal escape 119 viruses that may initiate infection in the infant. Therefore, studying unique features of infant T/F 120 viruses and their neutralization-sensitivity determinants to maternal autologous virus neutralizing 121 antibodies may provide insights of the molecular events that lead to virus escape from maternal 122 humoral responses. 123
The use of broadly neutralizing antibodies as a treatment and/or prevention strategy is 124 currently being explored in adult and infant clinical trials [33, 34] . Among the new generation of 125 bNAbs, VRC01 (antibody recognizing CD4bs region) has been able to neutralize about 80% of diverse HIV-1 strains [35, 36] . This has lead to studies of VRC01 impact on HIV-1 infection in 127 adults and infants when infused passively, with a phase I study of pharmacokinetics and safety of 128 VRC01 in HIV-exposed newborns currently underway [37] . However, the susceptibility of infant 129 T/F viruses to bNAbs like VRC01 does not seem to define infant T/F viruses from maternal non-130 transmitted viruses [17] and administration of a bNAb to chronically-infected mothers is likely to 131 lead to rapid development of resistant viruses [34, 38] . Thus, defining the role of autologous 132 neutralization in MTCT is critical to establishing the utility of active maternal vaccination to 133 further reduce and eliminate infant HIV infections. 134
In this study, we characterized maternal non-transmitting and infant T/F viruses from 16 135
HIV-1 clade B infected peripartum transmission mother-infant pairs from the WITS cohort and 136
defined the role of concurrent maternal autologous virus neutralizing antibodies in selecting for 137 infant T/F viruses. We sought to define if neutralization resistance to paired maternal plasma was 138 a defining feature of infant T/F viruses compared to other circulating non-transmitted maternal 139 variants, which will inform the development of maternal or infant vaccination strategies to 140 further reduced MTCT risk to achieve an HIV-free generation. 141
Results

142
Maternal and infant sample characteristics 143
We selected sixteen, HIV-1 infected mother-infant transmission pairs from the WITS cohort that 144 met the inclusion criteria of peripartum transmission (infants tested negative for HIV-1 infection 145 at birth by HIV-1 DNA PCR, yet had HIV-1 DNA detectable at one week of age or older; see 146 Table1). These HIV-exposed infants had not reportedly been breastfed [22] . Infant plasma 147 samples available for sequencing were between 16 -74 days of age. Five HIV-infected infants 148 with heterogeneous virus populations were excluded from the study due to our inability to 149 confidently infer the infant T/F virus. The maternal plasma viral load of the selected transmitting 150 women ranged from 4,104 to 3,68,471 copies/mL, and peripheral blood CD4 + T-cell counts 151 ranged from 107 to 760 cell/mm 3 . Infant plasma viral loads varied between 11,110 and 2,042,124 152 copies/mL, and CD4 + T-cell counts were between 1,872 and 7,628 cell/mm 3 . All infants were 153 born via vaginal delivery except for three infants (100014, 100155, 100307) born via cesarean 154 section, thus potentially representing late in utero transmission. Four infants (100014, 100155, 155 100307, 102149) were born prematurely (31, 34, and 36 weeks respectively), and the remaining 156 infants were born between 37 and 40 weeks of gestation. Characterization of the complete env gene sequences from paired mother-infant plasma 163 A total of 463 env genes were obtained from 16 maternal plasma samples (collected at time of 164 delivery) from transmitting mothers as previously described [24] . Paired infant plasma samples were 165 used to obtain 465 env gene sequences (Table 2) . Neighbor-joining phylogenetic trees and 166 highlighter plots of the env sequences from each infant were used to define infant T/F viruses. These 167 analyses showed within-lineage low diversity populations in infant Env isolates and chronic-like 168 diversity in maternal env sequences ( Fig.1 , A-C and Fig. S1 A-B ). In 6 out of 16 (37%) infants we 169 detected 2 or 3 (in case of 100002) genetically distinct T/F variants, one of which was present at 170 higher frequency (primary T/F), while the second one was present at lower frequency (secondary 171 T/F). In the other 10 infants demonstrated we observed only one T/F virus (67%). With the 172 exception of two infants, all of our samples had over 20 infant sequences, giving us a 90% 173 confidence that we were able to sample all variants with a population frequency of at least 10%. For 174 the two infant samples for which we only had 15 and 18 sequences respectively, we were 90% 175 confident that we were able to sample all variants with a population frequency of 15% or more [24] . 176
Using an algorithm described in the Methods, out of these 463 maternal env variants, we selected 177 134 SGA variants for env pseudovirus production (5-12 per mother) to represent the env genetic 178 diversity found in the plasma of each transmitting mother at the time of delivery. 179 
Confirming the timing of infant HIV-1 infection 186
As the infants were selected for peripartum transmission, their age at sampling (in days) was also 187 the post-infection time. To confirm the time of infection, all infant alignments were analyzed 188 using the LANL Poisson Fitter tool [39] . For infants that had more than one T/F, only the 189 sequences in the major T/F lineage were used for this analysis. When recombinants and 190 APOBEC enrichment were detected, the timing was calculated after removing recombinants 191 and/or positions enriched for hypermutation [24, 39] . 192
All but one infant (102605) yielded a good Poisson fit, indicating that the amount of diversity 193 found in these samples was compatible with a random accumulation of mutations as observed in 194 acute infections. Four infants had detected recombinants and 6 infants yielded a good Poisson fit 195 after removing positions enriched for hypermutation ( Table 2) . The time since the most common 196 ancestor was consistent with transmission at delivery in 9 out of 16 pairs (57%), within the 95% 197 confidence interval of the Poisson Fitter time estimate (Table 2) . For three infants, Poisson Fitter 198 estimated the time since infection to be younger than the reported infant age, and for one the 199 infection showed more diversity than expected by the reported infant age. Discrepancies between 200 actual vs. predicted transmission timing could be due to a number of factors, including late in 201 utero infection, postpartum infection from unreported breastfeeding, and the model being 202 designed to evaluate an adult rather than infant HIV-1 evolution, which could gather mutations 203 more rapidly due to more robust T cell responses. 204
Infant 102605 env SGAs did not yield a good Poisson fit due to non-random accumulation of 205 non-synonymous mutations (which breaks the model assumption of random accumulation of 206 mutations) at HXB2 positions 752-754 ( Fig. S2 ). We looked at this region in the LANL 207 immunology database (https://www.hiv.lanl.gov/content/immunology/index), and found five different human CTL epitopes that have been documented in the literature, confirming that the 209 non-random mutations found in infant 102605 were likely due to selection pressure by T cell 210 responses. 211
Neutralization sensitivity and tier classification of the infant T/F viruses 212
Twenty When Infant T/F pseudoviruses were tested against the autologous plasma, only 2 infants 222 T/F (100046 and 100155) showed some sensitivity as per our criteria (ID 50 > 3X that of MLV) 223 while others were completely resistant. Some infant T/F pseudoviruses did show sensitivity 224 against their own plasma but were not considered as sensitive due to high reactivity against 225
MLV. 226
To determine whether these infant T/F env variants were globally resistant to heterologous 227 plasma neutralization, we performed neutralization tier phenotyping using a standardized panel 228
of heterologous plasma of HIV-1 infected individuals [40] . Thirteen (62%) of 21 infant T/F Env 229 pseudoviruses tested were classified as tier 2 neutralization phenotype while 3 (14%) of 21 were classified as tier 3 neutralization phenotype, as expected for infant T/F viruses (Fig. 2) . 231
Remarkably, the remaining 5 (24%) tested were classified as the easier-to-neutralize tier 1b or 232 tier 1a sensitivity, possibly because that these variants were uniquely resistant to their paired 233 maternal plasma (Fig. 2) . 234
In contrast to the relative resistance to paired maternal plasma neutralization, all the infant 235 T/F viruses were relatively sensitive to second-generation HIV-1 broadly neutralizing antibodies, 236 such as VRC-01, (IC 50 range 0.12-5.0 µg/ml), PGT121 (IC 50 range 0.01-0.13 µg/ml), NIH 45-46 237 (IC 50 range 0.01-0.28 µg/ml) and first generation bNAb 10E8 (IC 50 range 0.05-0.76 µg/ml) ( Fig.  238 3 and Fig. S3 ). Not surprisingly, the infant T/F Env pseudoviruses were less neutralization 239 sensitive to the less potent first generation broadly neutralizing antibodies b12 (IC 50 range 2.97-240 25 µg/ml), 4E10 (IC 50 range 1.31-18.73 µg/ml) and 2F5 (IC 50 range 1.01-19.09 µg/ml) ( Fig. 3) . 241
Importantly, all the infant T/F viruses were neutralization sensitive to VRC-01, a bNAb currently 242 being evaluated in clinical trials for use in HIV exposed infants. However, V3 glycan-specific 243 bNAbs, which clustered together in neutralization sensitivity, and NIH45-46 mediated the most 244 neutralization breadth and potency against the infant T/F viruses ( Fig. 3) . 
Neutralization sensitivity of non-transmitted maternal env variants compared to infant T/F 254 env variants 255
Pseudoviruses were prepared from a total of 134 non-transmitted maternal env variants using the 256 promoter PCR method [42] and assessed for neutralization sensitivity against paired maternal 257 plasma, including the isolated maternal non-transmitted variant that was most closely related to 258 the infant T/F variant. Variable neutralization sensitivity to paired maternal plasma was observed 259 in non-transmitted maternal variants, with some of the variants exhibited neutralization 260 sensitivity while others showed complete neutralization resistance ( Fig. 4 ). Comparison of 261 neutralization sensitivity between infant T/F Env variants and the identified closest maternal 262 variant within each mother-infant pair revealed no consistent pattern. Over a 2-fold increase in 263 sensitivity was observed for Env pseudoviruses of non-transmitted maternal variants that were 264 most closely related to infant T/F for 6 infants (100002, 100307, 100052, 102149, 102407 and 265 102605). In contrast, infant T/F Env pseudoviruses from 3 infants (100014, 100046 and 100504) 266
were more sensitive to maternal plasma than their most closely related maternal variants. 267
Yet, the infant T/F viruses were generally more resistant to the maternal plasma at 268 delivery than the non-transmitted viruses from mothers within each maternal-infant pair, with the 269 exception of 100046. However, since there were only 1 or 2 T/F viruses in each infant, we could 270 not perform statistical analysis to determine if the differences are statistically significant within 271 each pair. To determine whether infant T/F viruses were overall more resistant to maternal 272 plasma than the paired non-transmitted maternal viruses, we employed a 1-sided permutation test 273 to compare the neutralization sensitivity of maternal non-transmitted variants to the infant T/F 274 Env variants. Remarkably, infant T/F Env variants were overall significantly more resistant to 275 paired maternal plasma collected at delivery than non-transmitted maternal Env variants (p=0.01). Even when excluding the mother-infant pairs with high MLV neutralization (100014 277 and 100504), the infant T/F Env variants remained more resistant to neutralization than non-278 transmitted maternal variants (p=0.005). 279
To assess whether any particular epitope-specific neutralization sensitivity was distinct in 280 infant T/Fs compared to matched maternal variants, we determined the neutralization sensitivity 281 of 4 bNAbs targeting distinct vulnerable epitopes on HIV-1 Env: VRC-01 (CD4bs-specific) 282
(VRC-01), PG9 (V2 glycan-specific), DH429 (V3 glycan-specific), and DH512 (membrane 283 proximal external region -MPER-specific) ( Fig. 5 ). We used the same 1-sided permutation test 284 described above to assess for differences in neutralization sensitivity to these bNAbs in infant 285 T/Fs vs non-transmitted maternal sequences. Interestingly, we found that infant T/F viruses were 286 significantly more resistant to DH512 (MPER-specific) compared to non-transmitted maternal 287 sequences (p = 0.025 by 1-sided permutation test; p=0.045 when excluding the two mothers with 288 non-specific neutralization), while all other comparisons yielded no statistical significance ( Fig.  289   5) . 290
Signature sequence analysis of infant T/F variants to predict neutralization resistance 291
Because DH512 binds to the MPER region, we investigated the amino acid positions within 292 this epitope (positions 662-683) and identified 4 positions that were either associated with higher 293 maternal plasma neutralization (position 662, amino acid A, K, Q, or S were significantly more 294 resistant than the wild type E, p=9.9e-05, 1-sided permutation test), lower DH512 IC 50 (position 295 667 and 676, p=9.9e-04 and 0.003, respectively by 1-sided permutation test), or both (position 296 683, amino acid R was significantly more resistant than the wild type K (most frequent AA at 297 this position), p<1e-04 by 1-sided permutation test; Fig. 7) . However, when we looked at the Env sequences in individual mother-infant pairs, these amino acid residues that associated with 299 DH512 neutralization resistance were equally distributed across non-transmitted maternal 300 sequences and infant T/F viruses. Therefore, we could not to determine if T/F variants enriched 301 for neutralization resistance-conferring amino acids were more apt to be transmitted compared to 302 non-transmitted maternal variants. This could be due to the low sequence number within pairs, or 303 it could suggest that the wild type amino acids at these positions are associated with DH512 304 neutralization resistance but not necessarily transmission. T) were significantly associated with higher neutralization resistance to paired maternal plasma 318 (p<0.001 by 1-sided permutation test). However, as for the MPER residues, we observed that 319 these amino acids were equally distributed across non-transmitted maternal and infant T/F virus 320 sequences, indicating that none of these amino acid residues were directly involved with transmission risk. This discrepancy could partially be due to the heterogeneity at amino acid 322 residue position 308. Yet, 6 out of 14 transmitting mother-infant pairs exhibited distinct amino 323 acid residues at position 308 from the more frequently occurring histidine ( Fig. 7 ), suggesting 324 variability at this position could be overrepresented in transmitting pairs. 325
Discussion
326
While maternal and infant ART has considerably reduced rates of MTCT, pediatric HIV 327 infection remains a significant public health problem in areas of high HIV prevalence, with up to 328 16% of HIV-infected women still transmitting the virus to their infant globally [1] . It is likely 329 that a maternal or infant HIV-1 vaccine will be required to eliminate pediatric HIV [44] . Thus, the rate of multiple T/F transmissions in this mother-infant cohort is in line with or slightly 345 higher than sexual transmission modes, but lower than that of transmission via intravenous drug only, there may be distinct virologic or immunologic determinants in peripartum and postpartum 396 HIV transmission. Yet an important, a novel observation gleaned this study is that infant T/F 397 viruses' neutralization resistance to maternal plasma is not predictive of neutralization resistance 398 to heterologous plasma. Remarkably, the tiered categorization of infant T/F viruses ranged from 399 easy to neutralize tier 1 a viruses, to very difficult to neutralize tier 3 viruses, suggesting that 400 heterologous plasma neutralization resistance is not a defining feature of infant T/F viruses. 401
Specifically, 24% of infant T/F viruses isolated in this study were classified as "easy to 402 neutralize" tier 1b or tier 1a variants by a standard panel of heterologous plasma [40], consistent 403 with the hypothesis that these infant T/F viruses may be specifically resistant to maternal 404 antibodies that co-evolved with the transmitted variants. 405
Not unsurprisingly, the majority of infant T/F viruses were neutralization sensitive to a 406 number of second generation broadly neutralizing antibodies (Fig. 4) . This finding is clinically 407 relevant, as it suggests that infant passive immunization with second generation broad and potent 408 bNAbs to prevent HIV-1 transmission could be an effective strategy to block MTCT. 409
Interestingly, there is an ongoing passive immunization clinical trial of high-risk, HIV-exposed 410 infants with VRC01 (https://clinicaltrials.gov/ct2/show/record/NCT02256631). The uniform 411 sensitivity of these clade B infant T/F viruses isolated in our study to VRC01 neutralization 412 suggests that these viruses would be effectively neutralized by VRC01, suggesting that clade B 413 infant virus transmission may be blocked by VRC01. 414
To our knowledge, this is the largest study that has characterized infant T/F and maternal 415 viruses and their neutralization sensitivity to maternal autologous virus neutralizing responses. 416
Our study specifically addresses whether infant T/F viruses are defined by their neutralization 417 sensitivity to maternal autologous virus neutralizing antibodies in peripartum MTCT of HIV. 418
MTCT is a unique setting in which protective antibodies only need block autologous virus 419 variants circulating in blood to which the infant is exposed. The observation that infant T/F 420 viruses are neutralization resistant compared to non-transmitted maternal variants suggests that 421 the development of a maternal vaccine that boosts maternal autologous virus neutralizing 422 responses may be a viable strategy to further reduce MTCT risk. Maternal Env immunization 423 regimens with closely related, but not identical, Envs to maternal circulating virus populations 424 may elicit antibodies that target her autologous virus pool through the well-described immune 425 phenomenon of 'original antigenic sin' [59, 60] . Our central finding that maternal autologous 426 virus neutralization shapes the genetic bottleneck of peripartum transmission has important 427 implications in designing maternal Env vaccination strategies that can synergize with current 428 maternal ART treatment strategies help achieve an HIV-free generation. 429
Materials and Methods
430
Study Subjects and sample collection 431
Maternal and infant pairs from the WITS cohort that met the following criteria were selected: 432 peripartum transmission, infant plasma samples from < 2.5 months of age, and maternal samples 433 available from around delivery. Peripartum transmission was defined by negative a negative 434 PCR result or negative culture from peripheral blood samples collected within 7 days of birth 435
with subsequent a positive result 7 days after birth ( Table 1) . 436 437
Ethics Statement 438
Samples used in this study were obtained from an existing cohort named as Women Infant 439
Transmission Study (WITS). WITS cohort samples were received as de-identified material and 440 were deemed as research not involving human subjects by Duke University Institutional Review 441
Board (IRB). The reference number for that protocol and determination is Pro00016627. 94°C for 15 seconds, 58°C for 30 seconds, and 68°C for 4 minutes, followed by 1 cycle of 68°C 461 for 10 minutes. Round 2 conditions were one cycle of 94°C for 2 minutes, 45 cycles of 94°C for 462 15 seconds, 58°C for 30 seconds, and 68°C for 4 minutes, followed by 1 cycle of 68°C for 10 463 minutes. Round 2 PCR amplicons were visualized by agarose gel electrophoresis and sequenced 464 for envelope gene using an ABI3730xl genetic analyzer (Applied Biosystems). The final 465 amplification 3'-half genome product was ~4160 nucleotides in length exclusive of primer 466 sequences and included all of rev and env gp160, and 336 nucleotides of nef. Partially 467 overlapping sequences from each amplicon were assembled and edited using Sequencher (Gene 468
Codes, Inc). Sequences with double peaks per base read were discarded. Sequences with one 469 double peak were retained as this most likely represents a Taq polymerase error in an early round 470 of PCR rather than multiple template amplification; such sequence ambiguities were read as the 471 consensus nucleotide. Sequence alignments and phylogenetic trees were constructed using 472
ClustalW and Highlighter plots were created using the tool at 473 https://www.hiv.lanl.gov/content/sequence/HIGHLIGHT/highlighter_top.html.
Sequence Alignment 475
All maternal and infant envelope sequences were aligned using the Gene Cutter tool available at 476 the Los Alamos National Laboratory (LANL) website 477 (http://www.hiv.lanl.gov/content/sequence/GENE_CUTTER/cutter.html) and then refined 478 manually. Full-length envelope sequences were manually trimmed in Seaview [61]. The infant 479 T/F env virus sequences were visually identified looking at phylogenetic trees and highlighter 480 plots, and infant consensus sequences of the major T/F lineage were created using the LANL 481
Consensus Maker tool 482
(http://www.hiv.lanl.gov/content/sequence/CONSENSUS/consensus.html). For infants that were 483 infected by 2 or more distinct T/F viruses, the highlighter plots and phylogenetic trees were 484 rooted on the consensus of the major variant. 485
Infant T/F Virus Envelope Characterization 486
Maternal and infant envelope alignments were characterized using Bio-NJ phylogeny (Mega 6 487 Software) and highlighter plot 488 (http://www.hiv.lanl.gov/content/sequence/HIGHLIGHT/HIGHLIGHT_XYPLOT/highlighter.ht 489 ml). The number of infant T/F viruses was determined by visual inspection of both phylogenetic 490 trees and highlighter plots of infant-maternal env sequence alignments. Hypermutation was also 491 evaluated using the tool Hypermut 492 (http://www.hiv.lanl.gov/content/sequence/HYPERMUT/hypermut.html). Sequences with 493 significant hypermutation (p<0.1) were removed from the alignment and not included in further 494 analysis. When a sample was found to be overall enriched for hypermutation [24] , positions 495 within the APOBEC signature context were removed ( Table 2) . All 16 infant infections were 496 acute and we were able to time the infection using the Poisson Fitter method after removing putative recombinants and/or hypermutated sequences as described above. Days since infant 498 infection were calculated using the Poisson Fitter tool 499 (http://www.hiv.lanl.gov/content/sequence/POISSON_FITTER/ pfitter.html) which estimates the 500 time since infection based on the accumulation of random mutations from the most recent 501 common ancestor (MRCA) [39] . For infants infected with 2 or more T/F viruses, only the major 502 variant was analyzed to obtain the time since the infection. The defined mutation rate was 2.16e-503 5. Values were reported in days with a 95% confidence interval and a goodness-of-fit p-value. 504
Infant T/F SGA Cloning 505
Amplicons from the first round PCR product that matched the infant consensus sequence 506 (T/F virus sequence) were ligated into pcDNA3.1 Directional Topo vectors (Invitrogen) by 507 introducing a -CACC 5' end via a PCR reaction with the primers Rev19 (5'-508 ACTTTTTGACCACTTGCCACCCAT-3') and Env1A (5'-caccTTAGGCATCTCCT 509 ATGGCAGGAAGAAG-3'). Phusion® High-Fidelity PCR Master Mix with HF Buffer was 510 used according to the manufacturer's instructions (New England BioLabs). Plasmids were then 511 transformed into XL10 gold chemically competent Escherichia coli cells. Cultures were grown at 512 37°C for 16 hours. Colonies were selected for growth, and plasmids were minipreped and quality 513 controlled by restriction enzyme digestion using BamHI and XhoI (New England BioLabs). 514
Plasmids containing an insert of correct size were sequenced to confirm 100% sequence 515 homology with the original env infant consensus sequence. Plasmids were then prepared by 516
Megaprep (Qiagen) kit and re-sequenced to confirm. For three infants, 100046, 100383 and 517 101580, no single genome isolated matched 100% of nucleotides in the consensus sequence. 518
Therefore site-directed mutagenesis on a single nucleotide was performed to create an isolate 519 identical to the consensus sequence. Primers for site directed mutagenesis were designed using Agilent's QuikChange primer design program and Agilent's QuikChange II XL kit was used. 521
Sequencing of the clones was done to ensure 100% homology with the infant consensus 522 sequence. 523 After 48 h of incubation at 37°C, 100µl of medium was removed from the wells. 100µl of 533 luciferase reagent was added to each well and incubated at room temperature for 2 min. 100µl of 534 the lysate was transferred to a 96-well black solid plate (Costar), and the luminescence was 535 measured using the Bright-Glo™ luminescence reporter gene assay system (Promega). 536
Pseudovirus preparation 524
Neutralization Assays 537
Neutralizing antibody activity was measured in 96-well culture plates by using Tat-regulated T/F viruses was at least 3 times higher than the ID 50 versus SVA.MLV. 552
Env Virus Variant Tier Phenotyping Assay 553
Neutralization titers (ID50s) were determined essentially as described above using five plasma 554 samples from HIV+ individuals in chronic infection. The geometric mean titer (GMT) was 555 calculated in Microsoft Excel and tier phenotype was determined by comparing these values to 556 the GMTs of standard panels of viruses representing tier 1A, tier 1B and tier 2 viruses [40, 63] 557 using the same five HIV+ plasma samples. 558
Sequence Selection Algorithm 559
To select maternal non-transmitted variants and capture the most divergent sequences from the 560 infant T/F, we devised an algorithm as follows. The algorithm finds the most variable positions 561 in the amino acid alignment and ranks all sequences with respect to the frequencies at these 562 positions. Sequences are then selected starting from the most divergent based on motif coverage as observed in the alignment and in the phylogenetic tree (in other words, if a group of diverging 564 sequences all share the same motif, only one in the group and/or tree node is selected). 565
Statistical Analysis 566
To test whether infant transmitted viruses were statistically significantly more resistant to 567 maternal plasma than non-transmitted maternal sequences, we devised a 1-sided permutation 568 test. At each iteration, we randomly assigned the "transmitted" status to any one sequence in 569 each infant-mother pair, and then ranked the remaining sequences in the pair according to 570 maternal plasma responses. All ranks across all pairs were then summed. We repeated this 571 randomization 1,000 times and then calculated the p-value as the percentage of sum of ranks that 572 were above the observed sum of ranks, out of all randomizations performed. This method is 573 robust, as it does not make any underlying assumption of the distribution of the maternal 574 plasmas, and it preserves the within mother-infant correlation of the data. The same algorithm 575 was used to test whether specific amino acid positions conferred resistance to maternal plasma 576 and/or antibodies. This time the "transmitted" status that was reshuffled at each iteration was the 577 wild type amino acid. 578 between sequences that carry the wildtype amino acid at HXB2 positions 662, 676, 676, and 683, 811 compared with those that carry a mutant. These four positions were chosen because they yielded 812 a significant association with either maternal plasma responses (i.e. sequences carrying the 813 mutant were statistically significantly more resistant to maternal plasma) or with DH512 814 responses (i.e. sequences carrying the mutant were statistically significantly more resistant to DH 512) in the MPER epitope. P-values were obtained using a 1-sided permutation test (see Mother/Infant Pairs 10 00 02 10 00 14 10 00 46 10 00 52 10 03 07 10 03 83 10 07 11 10 08 90 10 09 97 10 14 21 10 21 49 10 24 07 10 26 05 10 01 55 10 05 04 10 19 84 10 00 02 10 00 14 10 00 46 10 00 52 10 03 07 10 03 83 10 07 11 10 08 90 10 09 97 10 14 21 10 21 49 10 24 07 10 26 05 10 01 55 10 05 04 10 19 84 10 00 02 10 00 14 10 00 46 10 00 52 10 03 07 10 03 83 10 07 11 10 08 90 10 09 97 10 14 21 10 21 49 10 24 07 10 26 05 10 01 55 10 05 04 10 19 84 
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